Psyence Biomedical Ltd. Common Shares (PBM) Stock Forecast: StockMap's 2-Week Call
PBM stock forecast: StockMap's model leans Underperform on Psyence Biomedical Ltd. Common Shares for the two weeks after the Nov 19 close, toward PBM trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on PBM since Aug 21; by chance, a call on the same dates was right 58% of the time.
Psyence Biomedical Ltd. Common Shares last closed at $2.86, +13.94% on the session.
Against the IVW growth benchmark the position is +16.27% over the forecast window.
Psyence Biomedical Ltd. Common Shares' market cap is $10.91M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).
Where PBM sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
44 daily calls for PBM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Psyence Biomedical Ltd. Common Shares is classified under Health Care / Biotechnology.
StockMap tracks Psyence Biomedical Ltd. Common Shares as the 355th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Psyence Biomedical Ltd. Common Shares ranks 193rd of 394 in the group, against a group median of -0.27.